Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential On February 20, Barclays began coverage of Bristol-Myers Squibb Company (NYSE:BMY) with an Overweight rating and a $75 price target. The analyst acknowledged that the company is approaching a difficult period, pointing to a “patent cliff” as exclusivity for key drugs like Eliquis and Opdivo moves closer to ex ...